Something old, something new combine for effective vaccine against parasitic skin disease

September 24, 2020

COLUMBUS, Ohio - Scientists are planning for Phase 1 human trials of a vaccine they developed by using CRISPR gene-editing technology to mutate the parasite that causes leishmaniasis, a skin disease common in tropical regions of the world and gaining ground in the United States.

In a series of animal studies, the vaccine protected mice against the disease - including mice with compromised immune systems and mice exposed to the parasite in the same way humans are, through the bite of infected sand flies.

"If you assure protection in the sand fly model, then you have a good shot at a real vaccine," said Abhay Satoskar, a co-lead investigator of the work and professor of pathology and microbiology at The Ohio State University.

The team applied the new technology to the century-old Middle Eastern practice of leishmanization - deliberately introducing the live parasite to the skin to create a small infection that, once healed, leads to life-long immunity against further disease.

"Live vaccines like that are the best vaccines, but there's a potential risk of causing serious disease in some people," Satoskar said. "We refined the concept using modern technology, making a parasite that does not cause clinical disease but allows for induction of immunity."

The research was published recently in Nature Communications.

An estimated 1.5 million new cases of cutaneous leishmaniasis, caused by the Leishmania major parasite, are diagnosed worldwide each year, primarily in tropical and subtropical regions of the world - but also in southern Texas.

Leishmania in all of its forms is considered a neglected disease, mostly affecting populations in warm-weather developing countries - currently infecting about 12 million in all. But Satoskar noted that with global warming, it's only a matter of time until the southern United States is considered a subtropical region.

"As the warmth moves up toward the United States, the disease will move up," he said.

The standard treatment of more severe cases can be expensive, require multiple daily drug injections and cause unpleasant side effects, leading to poor patient compliance that allows parasites to develop resistance to the drugs.

To develop the vaccine, the researchers set out to use CRISPR to edit the genome of Leishmania major. The precision technology enabled the researchers to delete centrin, the gene for a protein that supports the parasite's physical structure, as well as remove an antibiotic resistance marker gene that is needed to be introduced into the parasite for removal of the centrin gene.

To cause infection, these parasites hijack immune cells and use those host cells to replicate indefinitely. The study showed that the mutant parasite lacking centrin can still find its way into cells and make copies of itself, but for only a limited amount of time and not at a pace that leads to clinical disease.

"So we're essentially using leishmanization. CRISPR allowed us to do that," Satoskar said. "The parasites are unable to proliferate, so they die. But they persist in the body for eight or nine months, which is long enough to generate acquired immunity."

Numerous studies in mice, including immune-deficient animals, showed the mutant parasites did not cause skin lesions, but natural parasites did. In additional experiments, vaccinated and unvaccinated mice were subjected to injections of live parasites and bites from infected sand flies seven weeks after their shots. Ten weeks later, most non-immunized mice developed large skin lesions, but only one vaccinated mouse developed a visible lesion.

"The multiple animal tests also made sure the genome didn't revert back to normal," Satoskar said. "And we found that if a sand fly were to bite at the site of the vaccine and take mutated parasites into the wild, the parasites cannot survive. So it is environmentally safe."

The international team of researchers from the United States, Japan, Canada and India is identifying partners to manufacture the vaccine, aiming to begin a Phase 1 clinical trial within two years. Satoskar said the vaccine is likely to cost less than $5 a dose - compared to the $100 to $200 cost for treatment in the hardest-hit countries.

A much more severe form of the disease, visceral leishmaniasis, affects organs and is fatal if left untreated. The team has been using the same CRISPR technique to mutate the genome of the Leishmania donovani strain that causes visceral leishmaniasis, and preliminary data suggest a safe vaccine could be on the horizon.
-end-
The research was supported by the Global Health Innovative Technology Fund, the Canadian Institutes of Health Research, the U.S. Food and Drug Administration's Center for Biologics Evaluation and Research, the Intramural Research Program of the National Institutes of Health, the National Institute of Allergy and Infectious Diseases, and the Fonds de recherche du Québec - Santé.

The study was co-led by Hira Nakhasi of McGill University and Greg Matlashewski of the FDA Division of Emerging and Transfusion Transmitted Diseases. The FDA is a co-owner of two U.S. patents associated with the mutated Leishmania species.

Other Ohio State co-authors include Noushin Saljoughian and Greta Volpedo.

Contact: Abhay Satoskar, Abhay.Satoskar@osumc.edu; 614-366-3417

Written by Emily Caldwell, Caldwell.151@osu.edu; 614-292-8152

Ohio State University

Related Parasites Articles from Brightsurf:

When malaria parasites trick liver cells to let themselves in
A new study led by Maria Manuel Mota, group leader at Instituto de Medicina Molecular, now shows that malaria parasites secrete the protein EXP2 that is required for their entry into hepatocytes.

How deadly parasites 'glide' into human cells
A group of scientists led by EMBL Hamburg's Christian Löw provide insights into the molecular structure of proteins involved in the gliding movements through which the parasites causing malaria and toxoplasmosis invade human cells.

How malaria parasites withstand a fever's heat
The parasites that cause 200 million cases of malaria each year can withstand feverish temperatures that make their human hosts miserable.

New studies show how to save parasites and why it's important
An international group of scientists published a paper, Aug. 1, 2020, in a special edition of the journal Biological Conservation that lays out an ambitious global conservation plan for parasites.

More flowers and pollinator diversity could help protect bees from parasites
Having more flowers and maintaining diverse bee communities could help reduce the spread of bee parasites, according to a new study.

How Toxoplasma parasites glide so swiftly (video)
If you're a cat owner, you might have heard of Toxoplasma gondii, a protozoan that sometimes infects humans through contact with contaminated feces in litterboxes.

Parasites and the microbiome
In a study of ethnically diverse people from Cameroon, the presence of a parasite infection was closely linked to the make-up of the gastrointestinal microbiome, according to a research team led by Penn scientists.

Clocking in with malaria parasites
Discovery of a malaria parasite's internal clock could lead to new treatment strategies.

Feeding bluebirds helps fend off parasites
If you feed the birds in your backyard, you may be doing more than just making sure they have a source of food: you may be helping baby birds give parasites the boot.

Scientists discover how malaria parasites import sugar
Researchers at Stockholm University has established how sugar is taken up by the malaria parasite, a discovery with the potential to improve the development of antimalarial drugs.

Read More: Parasites News and Parasites Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.